Abstract:Hepatocellular carcinoma (HCC) is one of the most common digestive malignancies. HCC It ranges as the fifth most common cause of cancer mortality worldwide. While The prognosis of metastatic or advanced HCC is still quite poor. Recently, locoregional treatment, especially local ablation therapies, plays an important role in the treatment of HCC. Radiofrequency ablation (RFA) and high-intensity focused ultrasound (HIFU) ablation are the most common-used methods effective and feasible for treating HCC. However, the molecular mechanisms underlying the actions of ablation in the treatments for HCC and the HCC recurrence after ablation still are poorly understood. Hypoxia-inducible factor (HIF), the key gene switch for adaptive responses to hypoxia, has been found to play an essential role in the rapid aggressive recurrence of HCC after ablation treatment. In this review, we summarized the current evidence of the roles of HIF in the treatment of HCC with ablation. Fifteen relevant studies were included and further analyzed. Among them, three clinical studies suggested that HIF-1α might serve as a crucial role in the RAF treatment of HCC or the local recurrence of HCC after RFA. The remainder included experimental studies demonstrated that HIF-1, 2α might target the different molecules (e.g., BNIP3, CA-IX, and arginase-1) and signaling cascades (e.g., VEGFA/EphA2 pathway), constituting a complex network that promoted HCC invasion and metastasis after ablation. Currently, the inhibitors of HIF have been developed, providing important proof of targeting HIF for the prevention of HCC recurrence after IRFA and HIFU ablation. Further confirmation by prospective clinical and in-depth experimental studies is still warranted to illustrate the effects of HIF in HCC recurrence followed ablation treatment in the future.

The Role of Hypoxia Inducible Factor-1 in Hepatocellular Carcinoma.

Roles of Hypoxia-Inducible Factor in Hepatocellular Carcinoma under Local Ablation Therapies

Activation Of Pi3 Kinase/Akt/Hif-1 Alpha Pathway Contributes To Hypoxia-Induced Epithelial-Mesenchymal Transition And Chemoresistance In Hepatocellular Carcinoma

HIF-1α plays a role in the chemotactic migration of hepatocarcinoma cells through the modulation of CXCL6 expression.

Cancer Therapy by Targeting Hypoxia-Inducible Factor-1.

HIF-1α signaling: Essential roles in tumorigenesis and implications in targeted therapies

Hypoxic Microenvironment and Hepatocellular Carcinoma Treatment

Hypoxia-mediated Activation of Hypoxia-Inducible Factor-1Α in Head and Neck Squamous Cell Carcinoma: A Review

Small Molecules Targeting HIF-1α Pathway for Cancer Therapy in Recent Years

Role of hypoxia in the hallmarks of human cancer.

HIF-1α pathway: role, regulation and intervention for cancer therapy

The role and mechanisms of hypoxia inducible factor (HIF)-2 in cancer development

The Role of HIF in Angiogenesis, Lymphangiogenesis, and Tumor Microenvironment in Urological Cancers

Defining the role of hypoxia-inducible factor 1 in cancer biology and therapeutics

Hypoxia-regulated gene network in drug resistance and cancer progression

The Role of Hypoxia‐inducible Factor 1 in Tumor Immune Evasion

Role of Hypoxia‑inducible Factor‑2α in Lung Cancer (Review).

Hypoxia and Hypoxia-inducible Factor-1α:Master Regulators of Tumor Metastasis

Effect of the Hypoxia Inducible Factor on Sorafenib Resistance of Hepatocellular Carcinoma

Hypoxia, Metabolic Reprogramming, and Drug Resistance in Liver Cancer

[Hypoxia-Inducible Factor-1Alpha: a Promising Target for Tumor Therapy].